Morse corporate partner John Hession, will moderate two upcoming programs for MassBio. The first program, Communicating Effectively to Get to the Next Level of Greatness, will take place on October 23, 2019 from 8:00 AM to 10:00 AM at the MassBio Offices. Read a brief description of the program below:
“Research shows that 9 out of 10 conversations miss the mark. How can you expect to create the next great team, company or life-saving drug if people walk away from conversations with different views of reality and what they agreed upon 90% of the time? Being a highly skilled and versatile communicator is vital in today’s marketplace for your success as a team member or leader. Whether you’re in a leadership role now, or seeking one, the ability to understand different behavioral styles, how to adapt your style and build trust and rapport to effectively communicate and lead is a top skill you need to have.”
Other speakers for this event include: Mark Cote, Business/Executive Coach, FocalPoint Business Coaching; Molly Hoult, Senior Principal. Promidian Consulting; and Gael O’Brien, Executive Coach, Presenter, Leadership Columnist at Strategic Opportunities Group.
The second program is on November 12, 2019 from 8:00 AM to 10:00 AM at the MassBio Offices. New Biotech Funding Model — New Wine in Tech Funding Bottles will address:
“Early stage financing and company creation models have evolved significantly over the last 20 years from heavily funded brick & mortar do or die entities to VC enabled minimalistic proof of concept start-ups with hand selected management. We’ll examine the current models in vogue today, the investor landscape, the impact of advancing science and technology, new types of partnerships and the novel approaches early stage companies are executing to advance to the next stage of existence. Finally, our panel will provide their ideas on the future of venture funding and early stage models and open it up to discussion with the audience.”
This panel will include: Gary Paul Magnant, MS, Managing Partner at ICV Venture Engineering Funds and Steve Gullans, President & CEO at Gemphire Therapeutics.
Additional events on similar topics can be found on the MassBio Events page.